 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...1112131415161718192021...123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Effects of Short-Term Lenvatinib Administration Prior to Transarterial Chemoembolization for Hepatocellular Carcinoma. (Pubmed Central) - May 11, 2024
The short-term LEN-TACE is feasible and safe, demonstrating promising outcomes with a high CR ratio, contributing to lipiodol retention in the tumor after cTACE, and extended PFS. To confirm the advantages of this treatment protocol, a prospective clinical trial is mandatory.
- | Tyvyt (sintilimab) / Eli Lilly, irpagratinib (ABSK011) / Abbisko, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Improvements in advanced hepatocellular carcinoma to repeat implementation of primary protocol after cancer progression occurs following sequential systemic therapy and a clinical trial: A case report. (Pubmed Central) - May 10, 2024
To confirm the advantages of this treatment protocol, a prospective clinical trial is mandatory. The combined treatment of TACE plus systemic therapy might be an appropriate subsequent treatment.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation (clinicaltrials.gov) - May 10, 2024
P1/2, N=62, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Journal, Metastases: IMPACT OF SYSTEMIC TREATMENTS FOR ADVANCED THYROID CANCER ON THE ADRENAL CORTEX. (Pubmed Central) - May 9, 2024
Our data confirm that systemic treatments for advanced thyroid cancer can lead to an impaired cortisol secretion. A reduction in the other hormones secreted by the adrenal cortex has been firstly reported and should be considered in the more appropriate management of these fragile patients.
- || Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - May 9, 2024
P2, N=29, Completed, Sponsor: Virginia G. Kaklamani
A reduction in the other hormones secreted by the adrenal cortex has been firstly reported and should be considered in the more appropriate management of these fragile patients. Unknown status --> Completed
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy: AK104-IIT-C-M-0035: Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 8, 2024
P2, N=30, Recruiting, Sponsor: Hunan Cancer Hospital
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: QUILT 502: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (clinicaltrials.gov) - May 8, 2024
P1/2, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Unknown status --> Completed Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Estrogen induces LCAT to maintain cholesterol homeostasis and suppress hepatocellular carcinoma development. (Pubmed Central) - May 8, 2024
Collectively, this study reveals that estrogen upregulates LCAT to maintain cholesterol homeostasis and dampen hepatocarcinogenesis. LCAT and HDL-C represent potential prognostic and therapeutic biomarkers for targeting cholesterol homeostasis as a strategy for treating HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus (Pubmed Central) - May 8, 2024
LCAT and HDL-C represent potential prognostic and therapeutic biomarkers for targeting cholesterol homeostasis as a strategy for treating HCC. No abstract available
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical data, Journal, HEOR, Monotherapy, Real-world evidence, Real-world: Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States. (Pubmed Central) - May 7, 2024
No abstract available The current study reinforces the clinical effectiveness of first line lenvatinib as standard of care in patients with RAI-R DTC in real-world clinical practice in the US.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. (clinicaltrials.gov) - May 7, 2024
P4, N=300, Recruiting, Sponsor: Chen Xiaoping
The current study reinforces the clinical effectiveness of first line lenvatinib as standard of care in patients with RAI-R DTC in real-world clinical practice in the US. Not yet recruiting --> Recruiting
- || Enweida (envafolimab) / 3DMed, Ascletis
Trial primary completion date, Metastases: Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer (clinicaltrials.gov) - May 7, 2024
P2, N=108, Recruiting, Sponsor: 3D Medicines (Sichuan) Co., Ltd.
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2024 --> Aug 2024
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Surgery: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma (clinicaltrials.gov) - May 6, 2024
P4, N=300, Recruiting, Sponsor: Chen Xiaoping
Trial primary completion date: Jan 2024 --> Aug 2024 Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. (Pubmed Central) - May 6, 2024
This follow-up report updated OS in patients with metastatic or recurrent thymic carcinoma. A higher RDI of lenvatinib at 8
- | Journal: Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B. (Pubmed Central) - May 6, 2024
Furthermore, our experience supports the view that serial calcitonin measurements may be more sensitive than radiological follow-up in advanced MTC. Our patient also represents a new case of rarely reported calcitonin-producing pheochromocytomas.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase 3 ENGOT-En9/LEAP-001 Study: Lenvatinib + Pembrolizumab (LEN/PEMBRO) vs Chemotherapy (Chemo) as First-Line (1L) Therapy for Advanced or Recurrent Endometrial Cancer (Auditorium) - May 3, 2024 - Abstract #ESMOGC2024ESMO_GC_107;
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. (Pubmed Central) - May 3, 2024
The results suggest that abnormal activation of pathways, drug transport, epigenetics, tumour microenvironment, cancer stem cells, regulated cell death, epithelial-mesenchymal transition, and other mechanisms are involved in the development of lenvatinib resistance in HCC and subsequent HCC progression. To improve the therapeutic outcomes of lenvatinib, inhibiting acquired resistance, combined therapies, and nano-delivery carriers may be possible approaches.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. (Pubmed Central) - May 2, 2024
To improve the therapeutic outcomes of lenvatinib, inhibiting acquired resistance, combined therapies, and nano-delivery carriers may be possible approaches. The combination of pembrolizumab and lenvatinib did not show sufficient response in patients with NETs to warrant continued enrollment on trial.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Retrospective data, Journal: Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Apr 30, 2024
The combination of pembrolizumab and lenvatinib did not show sufficient response in patients with NETs to warrant continued enrollment on trial. ATZ/BEV merits consideration even for MTA-experienced patients, since the OS was equivalent to those in MTA-na
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. (Pubmed Central) - Apr 30, 2024
ATZ/BEV merits consideration even for MTA-experienced patients, since the OS was equivalent to those in MTA-na The combination of HAIC-FOLFOX with lenvatinib and PD-1 inhibitors as a first-line therapy has exhibited notable therapeutic efficacy and well-tolerated adverse events among patients with high-burden HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Observational data, Retrospective data, Journal: Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. (Pubmed Central) - Apr 29, 2024
In conclusion, the proteinuria grade was not significantly associated with decreased eGFR under UPCR monitoring in our study. Therefore, lenvatinib can carefully be continued targeting UPCR of less than 3.5 g/gCre.
- || Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Clinical Trial,Phase II, Journal: Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. (Pubmed Central) - Apr 29, 2024
P2
Therefore, lenvatinib can carefully be continued targeting UPCR of less than 3.5 g/gCre. Tislelizumab plus lenvatinib demonstrated promising antitumor activity with favourable tolerability as first-line therapy for patients with uHCC.
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (clinicaltrials.gov) - Apr 28, 2024
P2, N=30, Not yet recruiting, Sponsor: Harbin Medical University
- || Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: LITESPARK-016: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (clinicaltrials.gov) - Apr 28, 2024
P2, N=730, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Tislelizumab plus lenvatinib demonstrated promising antitumor activity with favourable tolerability as first-line therapy for patients with uHCC. Trial completion date: Aug 2026 --> Mar 2027 | Trial primary completion date: Aug 2026 --> Mar 2027
- || Review, Journal: Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (Pubmed Central) - Apr 28, 2024
Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China. (Pubmed Central) - Apr 28, 2024
The evidence-based pricing strategy provided by this study could benefit decision-makers in making optimal decisions and clinicians in general clinical practice. More evidence about budget impact and affordability for patients is needed.
- | Cyramza (ramucirumab) / Eli Lilly
Retrospective data, Journal: Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Apr 28, 2024
Ramucirumab may be equally useful in patients with unresectable HCC who have poor liver function or whose liver function is aggravated by other therapies. Rechallenge treatment with lenvatinib after ramucirumab may be a valid treatment option for HCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report. (Pubmed Central) - Apr 27, 2024
As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Antiproliferative Activity of N-Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition. (Pubmed Central) - Apr 27, 2024
This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients. Multikinase inhibitors sorafenib (Nexavar
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Predictive insights into plant-based compounds as fibroblast growth factor receptor 1 inhibitors: a combined molecular docking and dynamics simulation study. (Pubmed Central) - Apr 26, 2024
To gain further insights into the conformational dynamics of Mundulone and the reference FGFR1 inhibitor, Lenvatinib, we conducted time-evolution analyses employing 200?ns molecular dynamics simulations (MDS) and essential dynamics...Overall, the findings indicate that Mundulone exhibits promising binding affinity, specific interactions, and favorable drug profiles, making it a promising lead candidate. Further experimental analysis will be necessary to confirm its effectiveness and safety profiles for therapeutic advancement in the cancer field.Communicated by Ramaswamy H. Sarma.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor-? signaling in their molecular effects. (Pubmed Central) - Apr 26, 2024
Our findings indicate that both sorafenib and lenvatinib possess anticancer abilities by inducing the cytotoxicity of hepatocellular carcinoma cells. Furthermore, they show opposing effects on TGF-?-induced cell invasion and angiogenesis, thereby enhancing the understanding of the multifaceted functions of molecular targeted drugs in treating hepatocellular carcinoma.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal: Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma. (Pubmed Central) - Apr 25, 2024
This study showed that TACE/lenvatinib/PD-1 treatment was well tolerated with encouraging efficacy in patients with unresectable HCC. The patients with BCLC B-stage disease with early NLR response (decrease) and early AFP response (decrease > 20%) may achieve better clinical outcomes with this triple therapy.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Review, Journal: Lenvatinib?based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta?analysis. (Pubmed Central) - Apr 25, 2024
These findings suggested that LEN-based combination strategies may confer efficacy and acceptable tolerability for patients with uHCC. In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile.
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients (clinicaltrials.gov) - Apr 25, 2024
P2, N=39, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| Kaitanni (cadonilimab) / Akesobio
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: AK104-206: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=59, Completed, Sponsor: Akeso
In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile. Recruiting --> Completed | N=30 --> 59 | Trial primary completion date: Apr 2023 --> Nov 2023
- || Kaitanni (cadonilimab) / Akesobio
Trial completion, Trial completion date, Combination therapy, Metastases: AK104-209: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 25, 2024
P2, N=32, Completed, Sponsor: Akeso
Recruiting --> Completed | N=30 --> 59 | Trial primary completion date: Apr 2023 --> Nov 2023 Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Aug 2023
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6917;
P2
Survival data is immature and will be updated in the future. Clinical trial information: NCT05410197.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
A retrospective study of PD-1/PD-L1 combination therapy versus TKI monotherapy in elderly patients with uHCC. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6911;
AEs and drug withdrawal rates are higher in the combination therapy group. Further discussions are needed to determine the optimal treatment strategy for elderly uHCC patients.
- Zepsun (donafenib) / Suzhou Zelgen, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6910;
This retrospective, single-center, real-world study demonstrated that when donafenib failed the regorafenib could still improve the prognosis of advanced HCC pts with fewer AEs. The study will continue to focus on overall survival(OS) and whether combined ICIs or not in the 1st-line/ 2nd-line treatment could have a positive effect on OS.
- Q-Force (quercetin) / Quercis Pharma, Temple University, Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Use of a nationwide, patient-powered observational platform to define the landscape of treatment, molecular profiling, and outcomes for fibrolamellar carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6878;
P=N/A
Aggregation of raw imaging scans is ongoing for central radiological review to measure depth and duration of response offered by the recorded therapeutic strategies. This dataset is a rich resource available to academic and government researchers to fuel research and define optimal treatment modalities.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6876;
Toxicity was manageable with a low incidence of grade 3-4 adverse events. There were no unexpected safety signals.
- Increase in blood pressure in patients with metastatic kidney cancer treated with combination checkpoint inhibitor and vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6855;
Our study demonstrates that in a real-world population of patients with metastatic ccRCC there is a statistically significant elevation of both SBP and DBP when treated with the combination of an ICI and VEGFR-TKI and that in those patients without baseline hypertension and not on anti-hypertensive therapy at baseline, there is a more pronounced increase in blood pressure. This data should reinforce the need to have close monitoring of SBP and DBP during therapy, regardless of whether the patient has underlying hypertension or not, and may help guide anti-hypertensive therapy during kidney cancer treatment.
- Tecentriq (atezolizumab) / Roche
Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6736;
P2
9 months) or the historical median OS of 5 months. Additional novel treatment strategies for patients with non-BRAF mutated ATC are warranted, especially when antiangiogenic drugs are contra-indicated.
- Utilizing stereotactic body radiation therapy in combination with tyrosine kinase inhibitors for therapeutic benefit in thyroid cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6711;
SBRT can be effectively and safely administered to achieve durable disease control in patients with aggressive thyroid cancer histology when combined with tyrosine kinase inhibitors. This strategy warrants evaluation in prospective clinical trials.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Treatment of iodine refractory well differentiated thyroid carcinoma: Real world data from a tertiary center in Mexico. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6708;
This strategy warrants evaluation in prospective clinical trials. Sorafenib and lenvatinib have shown comparable efficacy in prolonging progression-free survival in Mexican patients with metastatic/locally advanced, progressive, RAI-refractory DTC/PDTC, leading to markedly superior outcomes compared to pivotal studies.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, OC-001 / Ocellaris Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of envafolimab plus lenvatinib combined with etoposide in recurrent ovarian, peritoneal, and fallopian tube cancer: An open-label, single-arm study () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5983;
P2
The combination of envafolimab plus lenvatinib combined with etoposide shows promising efficacy and manageable toxicities in patients with platinum-resistant ovarian cancer. Clinical trial information: NCT05422183.
- Keytruda (pembrolizumab) / Merck (MSD)
Evaluation of body weight and race on pembrolizumab response in patients with endometrial cancer: A case control study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5927;
The study was underpowered to perform tests of statistical significance by race. These data preliminarily suggest pembrolizumab may not need to be adjusted for weight.
- Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5689;
P1/2
A significant proportion received subsequent lines of therapy post ICI, and exploration of ORR and PFS to next lines of therapy is of interest. Clinical trial information: NCT02538510 and NCT03749460.
- Immune checkpoint inhibitor-related reproductive adverse effects: A pharmacovigilance analysis based on the FAERS database. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5613;
Additional therapies could change the risk of irRAEs. Despite the current lack of high-quality clinical data on this topic, it is reasonable to inform patients about the plausible risk of irRAEs.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A prospective study of radiofrequency ablation combined with systematic neoadjuvant therapy in the treatment of recurrent hepatocellular carcinoma (RANT study). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5478;
P=N/A
Radiofrequency ablation combined with systematic neoadjuvant therapy exhibited promising efficacy and favorable safety for recurrent HCC. Clinical trial information: NCT05277675.